Amongst the present therapeutic class, hormone therapies hold the highest share amongst the other therapeutic options available for treating PWS. Increased awareness of the disease, assisted by organizational support and the promising pipeline of therapies, is expected to fuel market growth.
DelveInsight’s “Prader-Willi Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Prader-Willi Syndrome market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Prader-Willi Syndrome market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Prader-Willi Syndrome: An Overview
According to the US National Library of Medicine, Prader-Willi syndrome is a complex genetic condition affecting many body parts. This condition is characterized by weak muscle tone (hypotonia), feeding difficulties, poor growth, and delayed development in infancy. Beginning in childhood, affected individuals develop an insatiable appetite, which leads to chronic overeating (hyperphagia) and obesity. Some people with Prader-Willi syndrome, particularly those with obesity, also develop type 2 diabetes (the most common form of diabetes).
The disease occurs due to the loss of function of several genes in a particular region of chromosome number 15. Among these are genes that provide instructions for making molecules called small nucleolar RNAs (snoRNAs). Although considered a “rare” disorder, PWS is one of the most common conditions seen in genetic clinics and is the most common genetic cause of obesity that has been identified to date.
Prader-Willi Syndrome Market Key Facts
According to DelveInsight, the prevalent population of Prader-Willi Syndrome was estimated to be 47,500+ in the 7MM in 2018. The United States accounts for the highest number of Prader-Willi cases.
Among the EU5 countries, Germany had the highest prevalent patient population of Prader-Willi Syndrome, followed by Italy.
As per Foundation for PWS Research, Prader-Willi Syndrome occurs in approximately one out of every 15,000 births, it affects males and females with equal frequency and affects all races and ethnicities.
The estimates place the incidence between 1 in 10,000-30,000 individuals in the general population, while as per “Adult Prader-Willi Syndrome: An Update on Management by Luk Ho-Ming,” the incidence is about 1 in 15,000–25,000 live births.
Upcoming therapies, such as DCCR (Soleno Therapeutics), LV-101 (Levo Therapeutics) and Lariglutide (Novo Nordisk), have the potential to create a positive shift in the PWS therapeutics market in the coming years. The expected launch of potential therapies will lead to an increase in the market size of Prader-Willi Syndrome (PWS) in the coming years.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Prader-Willi Syndrome market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Prader-Willi Syndrome market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Prader-Willi Syndrome Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
The Report Covers the Prader-Willi Syndrome Epidemiology Subtype Segmented by –
Prevalent cases of Prader-Willi Syndrome
Diagnosed cases of Prader-Willi Syndrome
Prader-Willi Syndrome cases by Mutation types
Prader-Willi Syndrome associated clinical Manifestation
Prader-Willi Syndrome Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of potential drugs recently launched in the Prader-Willi Syndrome market or expected to be launched during the study period. The analysis covers the Prader-Willi Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Prader-Willi Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Prader-Willi Syndrome Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/prader-willi-syndrome-market
Prader-Willi Syndrome Therapeutics Market Outlook
Currently, there is no cure for Prader-Willi Syndrome. The lives of individuals with Prader-Willi Syndrome can be improved with an early diagnosis and careful management of symptoms, but more effective therapies are needed. The Prader-Willi Syndrome treatment is currently based on treating the disorder’s symptoms as they arise. Growth hormone deficiency is present in almost all children and many adults with PWS. In multiple studies, human growth hormone (HGH) benefits those with Prader-Willi syndrome.
The Leading Companies in the Prader-Willi Syndrome Therapeutics Market Include:
LG Life Sciences
And Many More
Prader-Willi Syndrome Drugs Covered in the Report Include:
Diazoxide choline controlled release (DCCR): Soleno Therapeutics
Intranasal carbetocin (LV-101): Levo Therapeutics
Livoletide or AZP-531
And Many Others
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Prader-Willi Syndrome Competitive Intelligence Analysis
4. Prader-Willi Syndrome Market Overview at a Glance
5. Prader-Willi Syndrome Disease Background and Overview
6. Prader-Willi Syndrome Patient Journey
7. Prader-Willi Syndrome Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Prader-Willi Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Prader-Willi Syndrome Unmet Needs
10. Key Endpoints of Prader-Willi Syndrome Treatment
11. Prader-Willi Syndrome Marketed Products
12. Prader-Willi Syndrome Emerging Drugs and Latest Therapeutic Advances
13. Prader-Willi Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Prader-Willi Syndrome Market Outlook (In US, EU5, and Japan)
16. Prader-Willi Syndrome Access and Reimbursement Overview
17. KOL Views on the Prader-Willi Syndrome Market
18. Prader-Willi Syndrome Market Drivers
19. Prader-Willi Syndrome Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
The “Prader-Willi Syndrome Pipeline Insight, 2022” report provides comprehensive insights about 18+ companies and 18+ drugs in the Prader-Willi Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. Some of the key players in the Prader-Willi Syndrome therapeutics market include Soleno Therapeutics, Levo Therapeutics, Inversago Pharma, Saniona, OptiNose, Helsinn, Radius Health, Rhythm, Tonix Pharma, Millendo Therapeutics, and many more.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States